form8_kjune92010.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 9, 2010
Progenics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
000-23143
|
|
13-3379479
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
| |
|
|
|
|
|
777 Old Saw Mill River Road, Tarrytown, New York
|
|
10591
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
Registrant's telephone number, including area code (914) 789-2800
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07. Submission of Matters to a Vote of Security Holders.
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) held its 2010 Annual Meeting of Stockholders on June 9, 2010. At the Meeting stockholders voted on (i) the election of nine directors of the Company; (ii) the approval of an amendment to the Company’s 1998 Employee Stock Purchase Plan; (iii) ratification of the Board of Directors’ selection of PricewaterhouseCoopers LLP to serve as the Company’s independent registered public accounting firm for 2010; and (iv) the discretion of the proxies to vote on the transaction of other business. The number of votes cast for and against or withheld with respect to each such matter and the number of abstentions and broker non-votes are set forth below.
| |
|
Votes For
|
|
Votes Against
|
|
Votes Withheld
|
|
Abstentions/
Broker Non-Votes
|
|
(i) Election of Directors
|
|
|
|
|
|
|
|
5,167,175
|
|
Kurt W. Briner
|
|
22,486,842
|
|
0
|
|
172,702
|
|
|
|
Charles A. Baker
|
|
20,975,073
|
|
0
|
|
1,684,471
|
|
|
|
Mark R. Baker
|
|
22,485,622
|
|
0
|
|
173,922
|
|
|
|
Peter J. Crowley
|
|
21,015,317
|
|
0
|
|
1,644,227
|
|
|
|
Mark F. Dalton
|
|
20,978,925
|
|
0
|
|
1,680,619
|
|
|
|
Stephen P. Goff, Ph.D.
|
|
14,486,094
|
|
0
|
|
8,173,450
|
|
|
|
Paul J. Maddon, M.D., Ph.D.
|
|
22,476,537
|
|
0
|
|
183,007
|
|
|
|
David A. Scheinberg, M.D., Ph.D.
|
|
21,991,316
|
|
0
|
|
668,228
|
|
|
|
Nicole S. Williams
|
|
22,506,742
|
|
0
|
|
152,802
|
|
|
| |
|
|
|
|
|
|
|
|
|
(ii) Approval of amendment of the 1998 Employee Stock Purchase Plan
|
|
21,908,250
|
|
656,677
|
|
94,617
|
|
5,167,175
|
| |
|
|
|
|
|
|
|
|
|
(iii) Ratification of selection of PricewaterhouseCoopers LLP
|
|
27,775,608
|
|
47,558
|
|
3,553
|
|
0
|
| |
|
|
|
|
|
|
|
|
|
(iv) Discretion on other business
|
|
9,527,667
|
|
18,187,079
|
|
111,973
|
|
0
|
Item 8.01. Other Events.
The Company today announced the election of board member Peter J. Crowley as Chairman of the Board at the Company’s Annual Meeting, replacing Kurt Briner, who stepped down as Chairman at the end of his term while remaining a director.
A copy of Progenics’ press release is attached hereto as Exhibit 99.1 and the information contained therein is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
|
99.1
|
Press Release dated June 10, 2010.
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PROGENICS PHARMACEUTICALS, INC.
By: /s/ ROBERT A. MCKINNEY
Robert A. McKinney
Chief Financial Officer, Senior Vice President,
Finance & Operations and Treasurer
Date: June 10, 2010